Cytopeutics is a Malaysian company specializing in providing mesenchymal stem cells (MSC) for clinical trials and treatments in the Asia-Pacific region. The company has been granted several U.S. patents for acute stroke, diabetes, and macular edema treatment with cell-based composition, as well as local patents for treatment involving heart, stroke, diabetes, and autoimmune disease. With over 12 years of experience, Cytopeutics has a track record of safety and efficacy in the region, along with published research papers and clinical trials on various diseases in collaboration with renowned universities. The company has been granted a clinical trial exemption (CTX) license to provide mesenchymal stem cells for clinical investigational use. Cytopeutics is also at the forefront of research exploring the potential of multicellular immunotherapy, including cytokine-induced killer cells (CIK) and polarized M2 macrophages.
Headquarters
Suite 2-3, 2Nd Floor, Bio X Centre, Persiaran Cyberpoint Selatan, Cyber 8
Cyberjaya; Selangor;
Postal Code: 63000
Contact Details: Purchase the Cytopeutics Sdn. Bhd. report to view the information.
Website: http://www.cytopeutics.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service